Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.

Abstract: This invention relates to Group 4 catalyst compounds containing di-anionic tridentate nitrogen/oxygen based ligands. The catalyst compounds are useful, with or without activators, to polymerize olefins, particularly a-olefins, or other unsaturated monomers. Systems and processes to oligomerize and/or polymerize one or more unsaturated monomers using the catalyst compound, as well as the oligomers and/or polymers produced therefrom are also provided.

Abstract: This invention relates to Group 4 dialkyl compounds supported by a pyridyl-amido-aryl (“PAA”), an anisole-amido-aryl (“AAA”), a phenoxy-amido-pyridyl (“PAPY”), an anisole-amido-phenoxy (“AAP”) or a anisole-amido-phenoxy (“AAP”) tridentate ligand. Such compounds can polymerize olefins, such as ethylene.

Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

Abstract: The present disclosure relates to a process for the preparation of a compound of formula (I) wherein R is hydrogen, a formyl group, a straight, branched or cyclic C1-C6 alkylcarbonyl group or a phenylcarbonyl group, or a salt thereof, characterized by the steps of reacting a compound of formula (II) with a mixture of Grignard initiator and Mg in a solvent to form a Grignard reagent, reacting the Grignard reagent with paraformaldehyde or trioxane to obtain a compound of formula (III) and then further reacting the compound of formula (III) in a known manner to obtain a compound of formula (I) and optionally salt formation.

Abstract: The invention relates generally to an improved process for manufacturing desvenlafaxine free base and salts or solvates thereof.

Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

Abstract: The present invention provides, inter alia, a novel process for the preparation of Citalopram, a known antidepressant.

Abstract: The present invention provides an efficient method of making O-desmethyl-venlafaxine.

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: Substituted amino compounds of general formula (I) ##STR1## are described, as are a method of preparing them and their use as drugs, especially as analgesics.

Abstract: A process for the preparation of tertiary diphenyl carbinols containing a primary or secondary amine substituent on the aliphatic moiety attached to the carbinol function which consists in contacting a Grignard phenyl reagent with an aminoacid wherein the mobile protons are not masked in an aprotic inert organic solvent or a mixture thereof at a temperature between 20.degree. C. and the boiling temperature by the reaction mixture.The reaction products are useful as active ingredients of medicaments and intermediates for the manufacture thereof.

Abstract: 4-mono- and di-isobutylamino butanols of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.1 and R.sup.2 are the same or different and each is selected from the group consisting of hydrogen, halo, hydroxyl, alkyl of 1 to 4 carbon atoms and alkoxy of 1 to 4 carbon atoms and R is hydrogen or isobutyl, are useful for the treatment of circulatory disorders, particularly arrhythmias, in humans and animals.

Abstract: A disazo compound is provided which is represented by the formula (I): ##STR1## (wherein, R.sub.1 and R.sub.2 each stands for hydrogen, a lower alkyl group with 1-4 carbon atoms, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted hetero ring group. R.sub.1 and R.sub.2 may be the same or different. And, R.sub.1 and R.sub.2 may mutually bond to form a ring).This disazo compound may be obtained by diazotating 2.6-diaminoanthraquinone and reacting the same with a coupler represented by the formula (IV): ##STR2## (wherein, R.sub.1 and R.sub.2 are the same as defined above). Further, a multilayer type electrophotographic element is provided which comprises a charge carrier generating layer and a charge transfer layer and uses, as a charge carrier generating substance, a disazo compound represented by the formula (I).

Abstract: New derivatives of 1,2-ethylenediamine and salts thereof endowed with vascular antispasmodic and antiallergic activity; processes for preparing them, some new intermediates useful in their preparation and pharmaceutical compositions containing them.

Abstract: .alpha.,.alpha.-Diaryl-.beta.-(tert-amino)-propanols having the general formula: ##STR1## wherein R', R" and R.sup.1 to R.sup.10 represent certain specific substituent groups, exhibit a diuretic and saluretic activity.Pharmaceutical composition containing at least one compound of the general Formula II together with a pharmaceutically acceptable diluent or carrier. The pharmaceutical compositions may be in a form suitable for oral or parenteral administration.